Renaissance Technologies (RenTech)'s GENB Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 39,685 shares of Generate Biomedicines, Inc. (GENB) worth $669,486, representing 0.00% of the portfolio. First purchased in 2026-Q2, this recently established position has been held for 1 quarters.
Based on recent 13F filings, Renaissance Technologies (RenTech) has initiated a new position in GENB, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Generate Biomedicines (GENB) Holding Value Over Time
Track share changes against reported price movement
Quarterly Generate Biomedicines (GENB) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +39,685 | New Buy | 39,685 | $16.87 |
Renaissance Technologies (RenTech)'s Generate Biomedicines Investment FAQs
Renaissance Technologies (RenTech) first purchased Generate Biomedicines, Inc. (GENB) in Q2 2026, acquiring 39,685 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Generate Biomedicines, Inc. (GENB) for 1 quarters since Q2 2026.
Renaissance Technologies (RenTech)'s largest addition to Generate Biomedicines, Inc. (GENB) was in Q2 2026, adding 39,685 shares worth $669,486.
According to the latest 13F filing for Q2 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 39,685 shares of Generate Biomedicines, Inc. (GENB), valued at approximately $669,486.
As of the Q2 2026 filing, Generate Biomedicines, Inc. (GENB) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Generate Biomedicines, Inc. (GENB) was 39,685 shares, as reported at the end of Q2 2026.